KPT-276

• Description:

  PKT-276, an analogue of PKT-185, is an oral bioavailable and selective inhibitor of nuclear output (SINE) . PKT-276 is also a CRM1 antagonist that irreversibly binds to and blocks the function of CRM1[1].

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  CRM1

• Type:

  Reference compound

• Related Pathways:

  Membrane Transporter/Ion Channel

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/kpt-276.html

• Concentration:

  10mM

• Purity:

  99.94

• Solubility:

  DMSO : 20 mg/mL (ultrasonic)

• Smiles:

  O=C(N1CC(F)(F)C1)/C=C\N2N=C(C3=CC(C(F)(F)F)=CC(C(F)(F)F)=C3)N=C2

• Molecular Formula:

  C16H10F8N4O

• Molecular Weight:

  426.26

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Ranganathan P, et al. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood. 2012 Aug 30;120 (9) :1765-73.|[2]Zhang K, et al. Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma. Exp Hematol. 2013 Jan;41 (1) :67-78.e4.|[3]Schmidt J, et al. Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276. Leukemia. 2013 Dec;27 (12) :2357-65.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  1421919-75-6